Explore

Rapid ReadRapid Read
Retension Pharmaceuticals Establishes Scientific Advisory Board to Advance Hypertension Treatment

Retension Pharmaceuticals Establishes Scientific Advisory Board to Advance Hypertension Treatment

Retension Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has announced the formation of its Scientific Advisory Board (SAB). This board comprises distinguished physicians and investigators specializing in hypertension, cardiovascular diseases, nephrology, and innovative cardiovascular trials. The SAB's primary role will be to provide strategic guidance and expertise in scientific, clinical trial, and therapeutic areas as Retension Pharmaceuticals progresses its lead compound, RTN-001, through its ongoing Phase 2b clinical trial for hypertension. Key members of the inaugural SAB include Luke J. Laffin, MD, from the Cleveland Clinic Lerner College of Medicine, who will chair the steering committee for the RTN-001 Phase 2b trial, and Ian Wilkinson, MD, Professor of Therapeutics at the University of Cambridge.
TrendlineTrendline
Janux Therapeutics Initiates Phase 1 Study for JANX013 in Metastatic Prostate Cancer

Janux Therapeutics Initiates Phase 1 Study for JANX013 in Metastatic Prostate Cancer

Janux Therapeutics Initiates Phase 1 Study for JANX013 in Metastatic Prostate Cancer
ReutersReuters
Experts urge FDA to set clear safety and access standards for psychedelic drugs

Experts urge FDA to set clear safety and access standards for psychedelic drugs

By Puyaan Singh and Kamal Choudhury Sept 14 (Reuters) - Doctors, veterans, pharmacists and therapists on Monday urged the U.S.
Rapid ReadRapid Read
Representatives Introduce Bipartisan Bill to Permanently Authorize Rare Pediatric Disease Priority Review Voucher Program

Representatives Introduce Bipartisan Bill to Permanently Authorize Rare Pediatric Disease Priority Review Voucher Program

U.S. Representatives Gus Bilirakis (R-FL), Nanette Barragán (D-CA), Kat Cammack (R-FL), Jake Auchincloss (D-MA), Tom Kean, Jr. (R-NJ), and Kevin Mullin (D-CA) have introduced bipartisan legislation to permanently authorize the U.S. Food and Drug Administration’s (FDA) Rare Pediatric Disease Priority Review Voucher (PRV) Program. This program, established in 2012, incentivizes the development of treatments for children suffering from rare and devastating diseases. The PRV program awards a transferable priority review voucher to companies that successfully develop and receive FDA approval for qualifying treatments. Since its inception, the program has facilitated the market entry of treatments for 47 rare pediatric diseases, a significant increase from the four FDA-approved treatments that existed before the program. The current authorization for the program is set to expire in 2029. The proposed permanent authorization aims to provide long-term certainty for researchers and investors, encouraging continued ...
Rapid ReadRapid Read
Tenaya Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for TN-401

Tenaya Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for TN-401

Tenaya Therapeutics, a clinical-stage biotechnology company, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for its gene therapy candidate, TN-401. This designation is for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), a serious heart disease. The RMAT designation is an expedited program designed to facilitate the development and review of regenerative medicine therapies for severe conditions where preliminary clinical evidence suggests the potential to address unmet medical needs. Tenaya's RMAT application included data from the RIDGE-1 clinical trial, which showed improvements in electrical stability measures, such as reduced rates of premature ventricular contractions (PVCs) and non-sustained ventricular tachycardias (NSVTs), common forms of ventricular arrhythmias in ARVC. The company's CEO, Faraz Ali, highlighted that this designation underscores the recognition of the seriousness of PK...
TrendlineTrendline
Drug Firms' Proprietary Data Significantly Boost AI Protein Model Performance

Drug Firms' Proprietary Data Significantly Boost AI Protein Model Performance

Drug Firms' Proprietary Data Significantly Boost AI Protein Model Performance
ReutersReuters
FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace

FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace

By Puyaan Singh and Kamal Choudhury Sept 14 (Reuters) - The U.S.
TrendlineTrendline
Viva Biotech Discusses Challenges and Opportunities in Cyclic Peptide Drug Development and Manufacturing

Viva Biotech Discusses Challenges and Opportunities in Cyclic Peptide Drug Development and Manufacturing

Viva Biotech Discusses Challenges and Opportunities in Cyclic Peptide Drug Development and Manufacturing
TrendlineTrendline
BioSpace Seeks Marketing Manager in Cambridge, MA for Rare Disease Launch

BioSpace Seeks Marketing Manager in Cambridge, MA for Rare Disease Launch

BioSpace Seeks Marketing Manager in Cambridge, MA for Rare Disease Launch
Rapid ReadRapid Read
Adelaide University Researchers Reprogram Immune Cells to Combat Solid Tumors Using Nanoparticle Technology

Adelaide University Researchers Reprogram Immune Cells to Combat Solid Tumors Using Nanoparticle Technology

Researchers at Adelaide University have developed a novel method utilizing messenger RNA (mRNA) technology and targeted lipid nanoparticles to reprogram tumor-associated macrophages (TAMs), a type of immune cell that typically helps tumors evade the body's defenses. This approach, detailed in Science Advances, aims to alter the tumor microenvironment rather than destroy immune cells. The nanoparticles are coated with an antibody that binds to TREM2, a protein highly expressed on TAMs, ensuring precise delivery. Once inside the macrophages, the particles release an mRNA molecule that instructs the cells to produce the chemokine CXCL9, and a compound called Resiquimod. Resiquimod prompts the macrophages to switch from an immune-suppressing state, while CXCL9 acts as a chemical beacon to attract cancer-fighting CD8+ T cells into the tumor. Preclinical animal models showed that this treatment reduced immune-suppressing macrophages by over 60% and increased CXCL9 levels fourfold, leading to greater infiltration...
Rapid ReadRapid Read
New Single-Molecule Technique Advances Tau Protein Mapping for Alzheimer's Research

New Single-Molecule Technique Advances Tau Protein Mapping for Alzheimer's Research

Scientists have developed a new method called Iterative Mapping of proteoforms, which allows for the measurement of intact protein forms, or proteoforms, at a single-molecule level and on an unprecedented scale. This technique was specifically demonstrated on tau proteins, which are implicated in Alzheimer's disease and other neurodegenerative conditions known as tauopathies. Unlike traditional proteomics methods that break proteins into peptides, Iterative Mapping preserves the integrity of each proteoform, enabling researchers to observe individual protein molecules directly. This approach provides a detailed understanding of the chemical modifications and sequence variants that define each proteoform, which can significantly influence a protein's behavior within a cell. The method has been validated using control samples and applied to model systems in tauopathy research, as well as human-derived brain tissue samples, offering a crucial link between experimental validation and real-world translational r...
Rapid ReadRapid Read
Retro Biosciences Adjusts Alzheimer's Drug Dosing in Clinical Trial

Retro Biosciences Adjusts Alzheimer's Drug Dosing in Clinical Trial

Retro Biosciences, a longevity startup backed by Sam Altman, is expanding its Phase 1 safety trial for the Alzheimer's drug RTR-242. The company is adding two new cohorts, increasing total enrollment by over 42% from 76 to 108 participants. This decision comes after initial doses of RTR-242 showed no significant side effects or safety signals. According to Retro CEO Joe Betts-LaCroix, the absence of any signal, even minor side effects, makes it difficult to assess the drug's efficacy at the current dosage. The drug is designed to target lysosomes, which are cellular recycling centers responsible for breaking down old proteins. This process, known as autophagy, tends to slow with age and is linked to neurodegenerative diseases like Alzheimer's and Parkinson's. RTR-242 aims to restore the acidity of aging lysosomes, thereby improving their function. The trial is currently testing the drug in healthy volunteers aged 18 to 65.